Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Paul M. Barr, MD, Alessandra Tedeschi, MD, Talha Munir, MD, Peter Hillmen, MD PhD, Jennifer Woyach, MD, John C. Byrd, MD, Paolo Ghia, MD PhD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Sandra Dai, PhD MS, Carlos Amaya-Chanaga, MD, James P. Dean, MD PhD, Susan M. o'Brien, MD

Blood (2019) 134 (Supplement_1): 3054.

https://doi.org/10.1182/blood-2019-123327

Published: 2019

Journal Articles

Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLL TM Real-World Registry

Anthony R. Mato, MDMSCE, Jacqueline C. Barrientos, MD MS, Danielle M. Brander, MD, John M. Pagel, MD PhD, Meghan Gutierrez, Karen Kadish, MSN, Brian Tomlinson, MPA, Nilanjan Ghosh, MD PhD, Nick Giafis, PhD, David Ipe, Sandhya Upasani, Murali Sundaram, MBA, PhD, Lucille Ferrante, MD, Carlos Amaya-Chanaga, MD, Reethi Iyengar, PhD, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 4425.

https://doi.org/10.1182/blood-2018-99-110566

Published: 2018

Journal Articles

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

Juliana Velez Lujan, BS,PhD, Michael Y. Choi, MD, Chaja Jacobs, MD, Colin McCarthy, BS, Alaina Heinen, BS, Carlos Amaya-Chanaga, MD, Thomas J. Kipps, MD PhD, Januario E Castro, MD

Blood (2018) 132 (Supplement 1): 1863.

https://doi.org/10.1182/blood-2018-99-118990

Published: 2018

Journal Articles

Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma Cytokine Levels

Juliana Velez Lujan, BS,PhD, Chaja Jacobs, MD, Paula A Lengerke Diaz, MD, Eider F Moreno-Cortes, MD, Cesar A Ramirez-Segura, BS, PhD, Michael Y. Choi, MD, Colin McCarthy, BS, Alaina Heinen, BS, Carlos Amaya-Chanaga, MD, Thomas J. Kipps, MD PhD, Januario E Castro, MD

Blood (2018) 132 (Supplement 1): 1864.

https://doi.org/10.1182/blood-2018-99-119523

Published: 2018

Journal Articles

Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL TM Real-World Registry

Jeff Sharman, MD, Jacqueline C. Barrientos, MD MS, Danielle M. Brander, MD, John M. Pagel, MD PhD, Meghan Gutierrez, Karen Kadish, MSN, Brian Tomlinson, MPA, Nilanjan Ghosh, MD PhD, Nick Giafis, PhD, David Ipe, Sandhya Upasani, Murali Sundaram, MBA, PhD, Lucille Ferrante, MD, Carlos Amaya-Chanaga, MD, Reethi Iyengar, PhD, Anthony R. Mato, MD MSCE

Blood (2018) 132 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2018-99-110562

Published: 2018

NARROW

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLL TM Real-World Registry

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma Cytokine Levels

Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL TM Real-World Registry

Email alerts

ASH Publications

American Society of Hematology

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLL TM Real-World Registry

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma Cytokine Levels

Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL TM Real-World Registry

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only